Eric Mark Green - 27 Feb 2024 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Signature
/s/ Luis Cantarero
Issuer symbol
WST
Transactions as of
27 Feb 2024
Net transactions value
-$18,881,657
Form type
4
Filing time
29 Feb 2024, 16:35:17 UTC
Previous filing
22 Feb 2024
Next filing
02 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WST Common Stock Options Exercise $3,679,894 +64,132 +42% $57.38 217,040 27 Feb 2024 Direct F1
transaction WST Common Stock Sale $23,077,971 -64,132 -30% $359.85 152,908 27 Feb 2024 Direct F1, F2
transaction WST Common Stock Options Exercise $516,420 +9,000 +6.3% $57.38 152,908 27 Feb 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WST Stock Option (Right to Buy) Options Exercise $0 -9,000 -49% $0.000000 9,316 27 Feb 2024 Common Stock 9,000 $57.38 Direct
transaction WST Stock Option (Right to Buy) Options Exercise $0 -64,132 -80% $0.000000 15,684 27 Feb 2024 Common Stock 64,132 $57.38 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.
F2 The price reported in Column 4 is a weighted average price.